Global burden of human papillomavirus and related diseases

D Forman, C de Martel, CJ Lacey, I Soerjomataram… - Vaccine, 2012 - Elsevier
The worldwide prevalence of infection with human papillomavirus (HPV) in women without
cervical abnormalities is 11–12% with higher rates in sub-Saharan Africa (24%), Eastern …

[HTML][HTML] Systematic review of the incidence and prevalence of genital warts

H Patel, M Wagner, P Singhal, S Kothari - BMC infectious diseases, 2013 - Springer
Abstract Background Anogenital warts (AGWs) are a common, highly infectious disease
caused by the human papillomavirus (HPV), whose high recurrence rates contribute to direct …

[HTML][HTML] Efficacy of quadrivalent HPV vaccine against HPV Infection and disease in males

AR Giuliano, JM Palefsky, S Goldstone… - … England Journal of …, 2011 - Mass Medical Soc
Background Infection with human papillomavirus (HPV) and diseases caused by HPV are
common in boys and men. We report on the safety of a quadrivalent vaccine (active against …

Portfolio theory: as I still see it

HM Markowitz - Annu. Rev. Financ. Econ., 2010 - annualreviews.org
This essay summarizes my views on (a) the foundations of portfolio theory and its
applications to current issues, such as the choice of criteria for practical risk-return analysis …

[HTML][HTML] The use of both therapeutic and prophylactic vaccines in the therapy of papillomavirus disease

AR Garbuglia, D Lapa, C Sias… - Frontiers in …, 2020 - frontiersin.org
Human papillomavirus (HPV) is the most common sexually transmitted virus. The high-risk
HPV types (ie, HPV16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59) are considered to be the …

Risk factors for and prevention of human papillomaviruses (HPV), genital warts and cervical cancer

C Chelimo, TA Wouldes, LD Cameron, JM Elwood - Journal of Infection, 2013 - Elsevier
Genital HPV infection is associated with development of cervical cancer, cervical neoplasia,
anogenital warts, and other anogenital cancers. A number of reviews have primarily …

Effect of the human papillomavirus (HPV) quadrivalent vaccine in a subgroup of women with cervical and vulvar disease: retrospective pooled analysis of trial data

EA Joura, SM Garland, J Paavonen, DG Ferris, G Perez… - Bmj, 2012 - bmj.com
Objectives To determine the effect of human papillomavirus (HPV) quadrivalent vaccine on
the risk of developing subsequent disease after an excisional procedure for cervical …

[HTML][HTML] Four year efficacy of prophylactic human papillomavirus quadrivalent vaccine against low grade cervical, vulvar, and vaginal intraepithelial neoplasia and …

Future I/II Study Group - The BMJ, 2010 - ncbi.nlm.nih.gov
Objectives To evaluate the prophylactic efficacy of the human papillomavirus (HPV)
quadrivalent vaccine in preventing low grade cervical, vulvar, and vaginal intraepithelial …

Quadrivalent human papillomavirus vaccination and trends in genital warts in Australia: analysis of national sentinel surveillance data

B Donovan, N Franklin, R Guy, AE Grulich… - The Lancet infectious …, 2011 - thelancet.com
Background Quadrivalent human papillomavirus (HPV) vaccine has high efficacy in clinical
trials but no reports describe its effects at a population level. From July, 2007, Australia was …

Burden and management of non-cancerous HPV-related conditions: HPV-6/11 disease

CJN Lacey, CM Lowndes, KV Shah - Vaccine, 2006 - Elsevier
Human Papillomavirus (HPV)-6 and-11 are the causative agents of ano-genital warts (GWs)
and recurrent respiratory papillomatosis (RRP). They are low-risk HPV types that are …